James Howard

Has grant

Professor

University of North Carolina at Chapel Hill

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

James Howard is a Professor at the University of North Carolina at Chapel Hill, USA. His research areas focus on myasthenia gravis and include the study of patient-reported symptoms, therapeutic innovations, and standardized outcome measures. His recent publications address the efficacy and safety of various treatments and the impact of therapies on clinical practices within the field.

Recent Grants

Grant: Close

VARIATIONS IN NEUROMUSCULAR SAFETY FACTOR

Open Date: 1985-01-01

Close Date: 1989-12-31

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (9)

Renato Mantegazza

Head

Fondazione IRCCS Istituto Neurologico Carlo Besta

ITALY

View details

Mazen Dimachkie

Professor & Neuromuscular Division Director

University of Kansas Medical Center

UNITED STATES

View details

Andreas Meisel

GERMANY

View details

Nicholas E Johnson

UNITED STATES

View details

Miloš Miljković

Chief Medical Officer

UNITED STATES

View details

Djillali Annane

FRANCE

View details

Kevin O'Connor

Associate Professor

Yale University School of Medicine

UNITED STATES

View details

Pushpa Narayanaswami

Professor of Clinical Neurology

Harvard University

UNITED STATES

View details

Sangwook Oh

Assistant Professor

Hallym University

SOUTH KOREA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

James Howard

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (20)

Reply to the Letter to the Editor: The Role of Patient‐Reported Symptoms in Standardizing MGFA Class 0 and MGFA‐PIS

Pain Experiences and Prescription Pain Medications Among People With Selected Muscular Dystrophies in the Muscular Dystrophy Surveillance, Tracking, and Research Network

Durability of Response to B‐Cell Maturation Antigen‐Directed mRNA Cell Therapy in Myasthenia Gravis

Standardization of Myasthenia Gravis Outcome Measures in Clinical Practice: A Report of the MGFA Task Force

Long‐Term Efficacy and Safety of Ravulizumab in Adults With Anti‐Acetylcholine Receptor Antibody‐Positive Generalized Myasthenia Gravis: Final Results From the Phase 3 CHAMPION MG Open‐Label Extension

The Impact of Efgartigimod on Utilization of Therapeutic Plasma Exchange Procedures for Myasthenia Gravis in One Tertiary Medical Center

In response to: “Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee” by Greco et al.

Time to response with ravulizumab, a long‐acting terminal complement inhibitor, in adults with anti‐acetylcholine receptor antibody‐positive generalized myasthenia gravis

US Clinical Practice Experience with Eculizumab in Myasthenia Gravis: Acute Clinical Events and Healthcare Resource Utilization

Engineering CAR-T therapies for autoimmune disease and beyond

Addressing Outcome Measure Variability in Myasthenia Gravis Clinical Trials

Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension

Clinicoserological insights into patients with immune checkpoint inhibitor‐induced myasthenia gravis

Racial and Ethnic Differences in Timing of Diagnosis and Clinical Services Received in Duchenne Muscular Dystrophy

Accuracy of the Scratch Collapse Test for Carpal Tunnel Syndrome in Comparison With Electrodiagnostic Studies

Long‐term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses

Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial

Telemedicine visits in myasthenia gravis: expert guidance and the myasthenia gravis core exam ( MG‐CE )

Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody–Positive Generalized Myasthenia Gravis

Reduced plasmablast frequency is associated with seronegative myasthenia gravis

Collaborators (9)

Renato Mantegazza

Mazen Dimachkie

Andreas Meisel

Nicholas E Johnson

Miloš Miljković

Djillali Annane

Kevin O'Connor

Pushpa Narayanaswami

Sangwook Oh

Make your next move.